...
首页> 外文期刊>ACS medicinal chemistry letters >Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization
【24h】

Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization

机译:发现新型4-芳基浓度作为抑制小管蛋白聚合的抗癌剂

获取原文
获取原文并翻译 | 示例
           

摘要

XJP-L (8), a derivative of the natural product (+/-)-7,8-dihydroxy-3-methylisochroman-4-one isolated from the peel of Musa sapien turn L., was found to exhibit weak inhibitory activity of tubulin polymerization (IC50 = 10.6 mu M) in our previous studies. Thus, a series of 4-arylisochromene derivatives were prepared by incorporating the trimethoxyphenyl moiety into 8, among which compound (+/-)-19b was identified as the most potent compound with IC50 values ranging from 10 to 25 nM against a panel of cancer cell lines. Further mechanism studies demonstrated that (+/-)-19b disrupted the intracellular microtubule network, caused G2/M phase arrest, induced cell apoptosis, and depolarized mitochondria of K562 cells. Moreover, ()-19b exhibited potent in vitro antivascular and in vivo antitumor activities. Notably, the R-configured enantiomer of (+/-)-19b, which was prepared by chiral separation, was slightly more potent than (+/-)-19b and was much more potent than the S-configured enantiomer in both antiproliferative and antitubulin assays. Our findings suggest that (+/-)-19b deserves further research as a potential antitubulin agent for the treatment of cancers.
机译:XJP-L(8),发现从Musa Sapien Turn L剥离中分离的天然产物(+/-) - 7,8-二羟基-3-甲基isochroman-4-一体化的衍生物表现出薄弱的抑制活性在我们以前的研究中,管蛋白聚合(IC50 =10.6μm)。因此,通过将三甲氧基苯基部分掺入8,制备一系列的4-芳基铬衍生物,其中鉴定化合物(+/-)-19b与IC50值鉴定为最有效的化合物,其对癌症患者的10至25nm细胞系。进一步的机制研究证明(+/-) - 19b破坏细胞内微管网络,导致G2 / M期阻滞,诱导的细胞凋亡和K562细胞的去极化线粒体。此外,()-19B在体外抗病毒和体内抗肿瘤活性表现出强大的体外抗病毒。值得注意的是,通过手性分离制备的(+/-) - 19b的R配置对映体比(+/-) - 19b略高,并且比抗增殖和抗增殖和抗增殖的映异构体更有效抗胰岛素测定。我们的研究结果表明,(+/-) - 19B值得进一步研究作为治疗癌症的潜在抗原剂。

著录项

  • 来源
    《ACS medicinal chemistry letters》 |2018年第10期|共11页
  • 作者单位

    China Pharmaceut Univ Dept Med Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Dept Med Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Dept Med Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Dept Med Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Dept Med Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Dept Med Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Dept Organ Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Dept Med Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

    Univ Nottingham Sch Pharm Div Mol Therapeut &

    Formulat Univ Pk Campus Nottingham NG7 2RD England;

    China Pharmaceut Univ Dept Med Chem 24 Tong Jia Xiang Nanjing 210009 Jiangsu Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;化学;
  • 关键词

    Combretastatin A-4; (+/-)-7; 8-Dihydroxy-3-methylisochroman-4-one; Tubulin inhibitors; Enantioseparation; Antitumor; Vascular disrupting;

    机译:组合A-4;(+/-) - 7;8-二羟基-3-甲基isochroman-4-one;小管蛋白抑制剂;映对;抗肿瘤;血管扰乱;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号